C-ADOIAlector
human genetics, neuroscience, immunology
modulatingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ADOI
C-ADOIC-ADOIhuman genetics, neuroscience, immunology
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Alector human genetics, neuroscience, immunology
Alector is developing therapies for devastating neurodegenerative diseases. Its pipeline is based on insights into human genetics, neuroscience, and immunology, with therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. The company focuses on diseases including frontotemporal dementia, Alzheimer’s disease, and amyotrophic lateral sclerosis.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Alector — Near-term readout · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic